Molecular Oncology

Papers
(The TQCC of Molecular Oncology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia‐inducible factor‐1α in colorectal cancer201
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM101
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities89
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy85
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection80
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 476
Issue Information68
66
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma65
Issue Information60
58
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2+ mononuclear phagocyte differentiation in liver cancer56
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis52
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors52
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy50
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer49
An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer49
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PDL1 immunotherapy in arm A of the NSGO49
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer46
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas45
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”40
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo37
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”36
ERK signaling controls productive HIF‐1 binding to chromatin and cancer cell adaptation to hypoxia through HIF‐1α interaction with NPM135
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer34
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity34
TGFβ selects for pro‐stemness over pro‐invasive phenotypes during cancer cell epithelial–mesenchymal transition34
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis33
Cancer‐associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T‐cell suppression33
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling33
Precision Cancer Medicine 2.0—Oncology in the postgenomic era32
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF132
An arms‐race against resistance: leukemic stem cells and lineage plasticity32
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation31
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1NDRG1 deregulation31
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer31
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system30
Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment30
Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP129
Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma29
Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread29
RETRACTION: Long Noncoding RNA ZNF667‐AS1 Reduces Tumor Invasion and Metastasis in Cervical Cancer by Counteracting Microrna‐93‐3p‐Dependent PEG3 Downregulation28
Issue Information28
RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells28
Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC28
Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer28
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models27
Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration27
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients26
Hijacking the BAF complex: the mechanistic interplay of ARID1A and EWS::FLI1 in Ewing sarcoma26
Cancer cachexia: biomarkers and the influence of age26
Academia and society should join forces to make anti‐cancer treatments more affordable25
Germline variants in CDKN2A wild‐type melanoma prone families25
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis25
Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor25
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinoma25
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia25
Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer25
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment25
Genomic characterization of small cell carcinomas of the uterine cervix25
Correction to: Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C25
ANGPTL2‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion24
The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival24
New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treat24
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers24
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer24
The transcribed ultraconserved region uc.160+ enhances processing and A‐to‐I editing of the miR‐376 cluster: hypermethylation improves glioma prognosis24
Replenishing co‐downregulated miR‐100‐5p and miR‐125b‐5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption23
Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T‐cell receptor sequencing23
Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion23
Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling23
NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR‐Akt feedback loop that activates autophagy23
DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC22
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK<22
Retraction statement: Consistency analysis of microRNA‐arm expression reveals microRNA‐369‐5p/3p as tumor suppressors in gastric cancer22
Issue Information22
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma22
LncRNA miR205HG hinders HNRNPA0 translation: anti‐oncogenic effects in esophageal carcinoma22
Sustained cancer‐relevant alternative RNA splicing events driven by PRMT5 in high‐risk neuroblastoma22
Tetraploidy‐linked sensitization to CENP‐E inhibition in human cells22
Issue Information21
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma21
DNA repair as a shared hallmark in cancer and ageing21
Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma21
Targeting protein folding in N‐Myc‐driven medulloblastoma21
MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness21
Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models21
Post‐prostatic‐massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate‐cancer‐typical microRNAs and activate proto‐oncogenes20
20
Cancer as an infective disease: the role of EVs in tumorigenesis20
Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR<20
Cancer outcome research – a European challenge Part II: Opportunities and priorities20
Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)19
Correction to “The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion”19
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential19
SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner19
Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy19
FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas19
Corrigendum to: Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population‐based testing program19
Rodent models of tumours of the central nervous system19
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies19
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment19
Abstracts18
CHML is an NRF2 target gene that regulates mTOR function18
Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity18
A rapid, multiplex digital PCR assay to detect gene variants and fusions in non‐small cell lung cancer18
KRAS inhibitors: going noncovalent18
MIB1 upregulates IQGAP1 and promotes pancreatic cancer progression by inducing ST7 degradation18
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers18
Lung cancer cells expressing a shortened CDK16 3′UTR escape senescence through impaired miR‐485‐5p targeting18
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients18
Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer18
Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach17
Assembly of glioblastoma tumoroids and cerebral organoids: a 3Din vitro model for tumor cell invasion17
A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL‐13Rα2‐mediated JNK‐AP‐1 signals17
Liver X receptors induce antiproliferative effects in basal‐like breast cancer17
Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation17
Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study17
MicroRNAs in blood act as biomarkers of colorectal cancer and indicate potential therapeutic targets17
Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis17
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance17
Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors17
The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer17
Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience17
Targeting cellular senescence to combat cancer and ageing17
CDH6‐activated αIIbβ3 crosstalks with α2β1 to trigger cellular adhesion and invasion in metastatic ovarian and renal cancers17
Lipid metabolism in B cell biology16
16
cAMP‐phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression16
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis16
Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial16
Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage16
Issue Information16
Issue Information16
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma16
Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer16
Retraction Statement: Circ‐TCF4.85 silencing inhibits cancer progression through microRNA‐486‐5p‐targeted inhibition of ABCF2 in hepatocellular carcinoma16
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B116
USP35 mitigates endoplasmic reticulum stress‐induced apoptosis by stabilizing RRBP1 in non‐small cell lung cancer16
Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial15
The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma15
Targeting senescence as an anticancer therapy15
Multiplex immune protein profiling of fine‐needle aspirates from patients with non‐small‐cell lung cancer reveals signatures associated with PD‐L1 expression and tumor stage15
Microglia and macrophages in glioblastoma: landscapes and treatment directions15
Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay15
Protein palmitoylation in cancer: molecular functions and therapeutic potential15
PP2A‐based triple‐strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells15
Liquid biopsy: from discovery to clinical implementation15
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells15
Immune escape of colorectal tumours via local LRH‐1/Cyp11b1‐mediated synthesis of immunosuppressive glucocorticoids14
Issue Information14
The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma14
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphory14
Issue Information14
A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin14
From bedside to portable and wearable: development of a conformable ultrasound patch for deep breast tissue imaging14
SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma14
GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL14
Copy number variations contribute to malignant tumor development in children with serious birth defects14
The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells14
Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice13
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy13
Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook13
Immune evasion: An imperative and consequence of MYC deregulation13
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation13
Current status of precision oncology in adult glioblastoma13
Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome13
Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β‐catenin signaling and tumor growth13
The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma13
Issue Information13
Expression of Concern: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma13
Thioredoxin‐interacting protein (TXNIP) is a substrate of the NEDD4‐like E3 ubiquitin‐protein ligase WWP1 in cellular redox state regulation of acute myeloi13
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients13
Enhanced reversal of ABCG2‐mediated drug resistance by replacing a phenyl ring in baicalein with a meta‐carborane13
Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTOR12
The roles and applications of extracellular vesicles in cancer12
Fragment‐based drug discovery—the importance of high‐quality molecule libraries12
12
12
Metabolism in the tumor cell and beyond12
Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β i12
CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma12
Issue Information12
12
ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma12
Characterization of fragment sizes, copy number aberrations and 4‐mer end motifs in cell‐free DNA of hepatocellular carcinoma for enhanced liquid biopsy‐based cancer detection12
Transcriptomic pan‐cancer analysis using rank‐based Bayesian inference11
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT rand11
Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library11
Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity11
Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy11
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype11
Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location11
Interferon regulatory factor 4 modulates epigenetic silencing and cancer‐critical pathways in melanoma cells11
Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals11
Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole‐exome sequencing11
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer11
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy11
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAFV600E mutated colorectal cancer—results from the FIRE‐4.5 study11
Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR411
Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment11
LIM domain‐containing protein Ajuba inhibits chemotherapy‐induced apoptosis by negatively regulating p53 stability in colorectal cancer cells11
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities11
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study11
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications10
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care10
Overexpression of the pro‐protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling10
Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent10
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives10
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework10
Viral mimicry evasion: a new role for oncogenic KRAS mutations10
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma10
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration10
Identification and targeting of a HES1‐YAP1‐CDKN1C functional interaction in fusion‐negative rhabdomyosarcoma10
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer10
Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study10
Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product10
Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis10
Enhancing therapeutic efficacy in triple‐negative breast cancer and melanoma: synergistic effects of modulated electro‐hyperthermia (mEHT) with NSAIDs especially COX‐2 inhibition in in vivo mod10
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis10
Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival10
Integrated analysis of racial disparities in genomic architecture identifies a trans‐ancestry prognostic subtype in bladder cancer10
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib10
Screening of an annexin‐A2‐targeted heptapeptide for pancreatic adenocarcinoma localization10
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer9
Proximity proteomics reveals role of Abelson interactor 1 in the regulation of TAK1/RIPK1 signaling9
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?9
Deciphering metabolic crosstalk in context: lessons from inflammatory diseases9
Immune‐related gene TM4SF18 could promote the metastasis of gastric cancer cells and predict the prognosis of gastric cancer patients9
The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging‐related disease9
PPM1D activity promotes the replication stress caused by cyclin E1 overexpression9
VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer9
Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients9
Sortilin‐related receptor is a druggable therapeutic target in breast cancer9
Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study9
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers9
In the spotlight: Julio Celis, the Founding Editor of Molecular Oncology9
Issue Information9
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials9
hnRNP‐A1 binds to the IRES of MELOE‐1 antigen to promote MELOE‐1 translation in stressed melanoma cells9
Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction9
High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion9
9
PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN‐deficient prostate cancers9
9
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization9
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance9
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells9
0.082350969314575